SCHEMBL807604

SCHEMBL807604

CC1CC(C(=O)O)CN(Cc2ccccc2F)C1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPK1 P28482 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
S1PR1 P21453 3/20 0.48
S1PR5 Q9H228 1/20 0.48
KDM4E B2RXH2 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
S1PR3 Q99500 2/20 0.47
POLB P06746 1/20 0.45
ATM Q13315 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
HTT P42858 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790831 0.86 ALDH1A1 (0.53) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL15084392 0.85 S1PR1 (0.46) ALDH1A1S1PR1S1PR5KDM4EMEN1
SCHEMBL15084377 0.84 ALDH1A1 (0.54) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL15084375 0.84 ALDH1A1 (0.54) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL1893898 0.80 ALDH1A1 (0.60) ALDH1A1MAPK1NPSR1S1PR5KDM4E
SCHEMBL807389 0.79 ALDH1A1 (0.49) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL15084388 0.78 CD274 (0.45) KDM4EMEN1KMT2AL3MBTL1
SCHEMBL30377416 0.76 ALDH1A1 (0.62) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL15082011 0.76 ALDH1A1 (0.45) ALDH1A1MAPK1NPSR1KDM4EMEN1
SCHEMBL806905 0.76 ALDH1A1 (0.45) ALDH1A1MAPK1NPSR1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2615916-B1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME (US) 2017-01-04 EP disclosed
EP-2615916-B1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME (US) 2017-01-04 EP disclosed
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 ALDH1A1 781/4885MAPK1 1/4885NPSR1 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.